Discovery and Therapeutic Exploitation of Mechanisms of Resistance to MET Inhibitors in Glioblastoma
Nichola Cruickshanks(Western University), Roger Abounader(University of Virginia), Fadila Guessous(University of Virginia), Ciana Deveau(National Institutes of Health), David Schiff(University of Virginia), Fang Yuan(Hunan Agricultural University), Julia Wulfkuhle(University of California, San Francisco), Karim Saoud(University of Virginia), Mary Pahuski(University of Virginia), Rosa I. Gallagher(George Mason University), Collin Dube(University of Virginia), Myron Gibert(University of Virginia), Cassandra Grello(University of Virginia), Ying Zhang(Sir Run Run Shaw Hospital), Baomin Wang(University of Virginia), See Phan, Sarah Hine(University of Virginia), Emanuel F. Petricoin(Center for Biologics Evaluation and Research), Madison Oxford(Penn State Milton S. Hershey Medical Center)
Cited by 45
Related Papers
A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma
|New England Journal of Medicine|2014|2.8k
Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions
|Neuro-Oncology|2020|1.1k
Response assessment criteria for brain metastases: proposal from the RANO group
|The Lancet Oncology|2015|1.1k
Therapeutic target database 2020: enriched resource for facilitating research and early development of targeted therapeutics
|Nucleic Acids Research|2019|830